| Symbol | PDSB |
|---|---|
| Name | PDS BIOTECHNOLOGY CORP |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 303A COLLEGE ROAD EAST, PRINCETON, NJ 08540 |
| Telephone | 800-208-3343 |
| Fax | — |
| — | |
| Website | https://www.pdsbiotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001472091 |
| Description | PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. Additional info from NASDAQ: |
(99% Neutral) PDS BIOTECHNOLOGY CORP (PDSB) Announces Business Combination
Read moreNew Form 424B5 - PDS Biotechnology Corp <b>Filed:</b> 2026-06-15 <b>AccNo:</b> 0001140361-26-025227 <b>Size:</b> 451 KB
Read moreNew Form PRE 14A - PDS Biotechnology Corp <b>Filed:</b> 2026-06-15 <b>AccNo:</b> 0001140361-26-025211 <b>Size:</b> 4 MB
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read more(99% Neutral) PDS BIOTECHNOLOGY CORP (PDSB) Announces Update on Collaboration with Common Stock
Read more(30% Negative) PDS BIOTECHNOLOGY CORP (PDSB) Reports Q2 2026 Financial Results
Read morePDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head … | Phase3 | Recurrent Head and Neck Cancer | Active_Not_Recruiting | 2025-05-30 | 2029-02-01 | ClinicalTrials.gov |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Rec… | Phase2 | Metastatic Head and Neck Cancer | Completed | 2021-03-29 | 2025-05-14 | ClinicalTrials.gov |
| NCT02065973 | An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerabil… | Phase1 | High-risk HPV Infection and Biopsy-proven CIN1 | Completed | 2014-02-01 | 2015-12-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 | Other | Phase PHASE1 | High-risk HPV Infection and Biopsy-proven CIN1 | COMPLETED | NCT02065973 |
| Pembrolizumab (KEYTRUDA®) and PDS0101 | Other | Phase PHASE2 | Metastatic Head and Neck Cancer | COMPLETED | NCT04260126 |
| Pembrolizumab Monotherapy | Drug | Phase PHASE3 | Recurrent Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT06790966 |
| Combination Treatment of PDS0101 and Pembrolizumab | Drug | Phase PHASE3 | Recurrent Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT06790966 |
| Pembrolizumab Monotherapy | DRUG | Phase PHASE3 | Recurrent Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT06790966 |
| R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 | BIOLOGICAL | Phase PHASE1 | High-risk HPV Infection and Biopsy-proven CIN1 | COMPLETED | NCT02065973 |